Introduction
Method
Search strategy
Databases | Number of abstracts |
---|---|
Web of science | 1191 |
TITLE: (autis*) AND TOPIC: (expen*) | 215 |
TITLE: (autis*) AND TOPIC: (cost*) | 500 |
TITLE: (autis*) AND TOPIC: (econom*) | 249 |
TITLE: (autis*) AND TOPIC: (spen*) | 94 |
TITLE: (autis*) AND TOPIC: (financ*) | 133 |
Medline through PubMed | 1333 |
(autis*[Title/Abstract]) AND (expen*[Title/Abstract]) | 183 |
(autis*[Title/Abstract]) AND (cost*[Title/Abstract]) | 617 |
(autis*[Title/Abstract]) AND (econom*[Title/Abstract]) | 285 |
(autis*[Title/Abstract]) AND (spend*[Title/Abstract]) | 97 |
(autis*[Title/Abstract]) AND (financ*[Title/Abstract]) | 151 |
Scopus | 1474 |
TITLE-ABS (autis* AND expen*) | 199 |
TITLE-ABS (autis* AND cost*) | 665 |
TITLE-ABS (autis* AND econom*) | 313 |
TITLE-ABS (autis* AND spend*) | 124 |
TITLE-ABS (autis* AND financ*) | 173 |
PICOS | Criteria |
---|---|
Population | Individuals with ASD |
Intervention | N/A |
Comparator | N/A |
Outcome | Contributing factors to healthcare costs in individuals with ASD |
Study design | Observational and experimental studies |
Inclusion criteria
Exclusion criteria
Data analysis
Results
Authous (Year) | Country | Study aim | Data source | Sample size (age) | Study perspective | Type of health services | Costs included in the study | Period of the study | ||
---|---|---|---|---|---|---|---|---|---|---|
Average direct costs per person | Average indirect costs per person | Average total costs per person | ||||||||
Jarbrink and Knapp (2001) [23] | UK | To estimate the economic consequences of autism in the UK | Secondary analysis of data | Autism with additional learning disabilities | Patient Provider | Hospital/inpatient services Medication use Other | OOP: $67,098 Provider spending: $221,027 | NR | NR | Lifetime |
High functioning autism | OOP: NR Provider spending: $152,717 | $298,256 | NR | |||||||
Jarbrink (2003) [24] | USA | To show the major cost drivers among children with ASD | Survey (Respondents: parents) | N = 17 (4–10 years) | Provider | Early intervention Health services Medication use | Provider spending: $416 | NR | NR | Weekly |
Liptak et al. (2006) [25] | USA | To compare healthcare expenditures between children with ASD and other children with and without disabilities | Survey (Respondents: parents) | N = 100 (< 17 years old) | Patient | Home/community-based/outpatient services
Hospital/inpatient services
Medication use
Respite care | OOP: $898 | NR | NR | Annual costs |
Flanders (2007) [26] | USA | To compare direct costs of treatment of children with ASD, asthma, and diabetes | Secondary analysis of data (California Medicaid Medical database) | N = 731 (3–17 years) | Payer | Hospital/inpatient services Outpatient services Medication use | Insurer spending: $6436 | NR | NR | Annual costs |
Jarbrink (2007) [27] | UK | To show the major cost drivers among children with ASD | Survey (Respondents: parents) | N = 55 (< 18 years old) | Provider | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | Provider spending: $3996 | NR | NR | Annual costs |
Leslie et al. (2007) [28] | USA | To examine the healthcare expenditures associated with ASDs in medical care settings | Secondary data analysis (Administrative claims database) | N = 613
(< 17 years old) | Payer Patient | Hospital/inpatient services Outpatient services Medication use | OOP + Insurer spending: $8531 | NR | NR | Annual costs |
Sharpe and Baker (2007) [29] | USA | To identify factors associated with financial problems in families that have a child with autism | Survey (Respondents: parents and care givers) | N = 333 (< 19 years old) | Patient | Hospital/inpatient services Outpatient services Respite care Medication use Other | NR | NR | NR | Annual costs |
Shimabukuro et al. (2008) [30] | USA | To estimate medical expenditures for children with ASD who receive employer-based health insurance | Secondary analysis of data (employer-based health insurance claims: the MarketScan research databases) | N = 3481 (1–21 years) | Payer Patient | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | OOP: $805 Insurer spending: $10,006 | NR | NR | Annual costs |
Knapp et al. (2009) [13] | UK | To estimate the costs of ASDs in the UK | Secondary analysis of data | Children with intellectual disability | Provider | Hospital/inpatient services Respite care Other | Provider spending: $11,946 | NR | NR | Annual costs |
Children without intellectual disability | Provider spending: $30,936 | NR | NR | |||||||
Young et al. (2009) [31] | USA | To examine the healthcare expenditures associated with ASDs in medical care settings. | Survey | N = 113 (2.5–21 years) | Patient | Hospital/inpatient services Outpatient services Respite care Medication use Other | OOP: $882 | NR | NR | Annual costs |
Wang et al. (2010) [32] | USA | To examine trends in health care expenditures associated with ASDs in state Medicaid programs | Secondary analysis of data (Medicaid data) | N = 69,542 (> 17 years old) | Payer | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | Insurer spending: $33,360 | NR | NR | Annual costs |
Barrett et al. (2012) [33] | UK | To determine family out-of-pocket expenses and productivity losses, and explore the relationship between family characteristics and costs. | Randomized controlled trial | N = 152 (2–4 years) | Patient Provider | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | OOP: $446 Provider spending: $2240 | $539 | $3792 | 6 months |
Parish et al. (2012) [34] | USA | To investigate the association between state Medicaid spending for children with disabilities and the financial burden reported by families of children with autism. | Secondary analysis of data (National Survey of Children with Special Healthcare Needs) | N = 2082 (< 18 years old) | Patients | NR | OOP: $690 | NR | NR | Annual costs |
Peacock et al. (2012) [10] | USA | To compare medical expenditures between children with ASDs and without ASDs | Secondary analysis of data (Health insurance claims: MarketScan Medicaid Multi-State Databases) | N = 8398 (2–17 years) | Payer | Hospital/inpatient services outpatient services Medication use | Insurer spending: $14,777 | NR | NR | Annual costs |
Wang et al. (2012) [35] | China | To determine the health expenses incurred by families of children with ASD and those expenses in relation to total patient income and expenditures | Survey (Respondents: parents) | N = 290 (1–15 years) | Patient | Home/community-based/outpatient services Respite care Medication use Other | OOP: $2936 | NR | NR | Annual costs |
Al-Farsi et al. (2013) [36] | Oman | To measure medical expenditures in children with ASDs | Survey (Respondents: parents) | N = 150 (< 15 years old) | Patient | Home/community-based/outpatient services Respite care Medication use Other | OOP:$346 | $961 | NR | Monthly |
Van Steensel et al. (2013) [37] | USA | To measure the societal costs of children with high-functioning ASD and comorbid anxiety disorder(s) | Survey (Respondents: parents) | N = 194 (7–18 years) | Patient | Home/community-based/outpatient services Respite care Medication use Other | OOP: $16,806 | NR | NR | Annual costs |
Raz et al. (2013) [38] | Israel | To measure the level of OOP expenditure for health services by families with autistic children | Survey (Respondents: parents) | N = 204 (4–10 years) | Patient | Home/community-based/outpatient services Respite care Medication use Other | OOP: $9930 | NR | NR | Annual costs |
Buescher et al. (2014) [9] | UK | To estimate lifetime societal economic costs among individuals with ASD | NR | NR | Patient | Medical services | Adults with ID: $8738 Adults without ID:$27,265 | NR | NR | Annual costs |
NR | Patient | Medical services | Children with ID:$1578 Children without ID: $1030 | NR | NR | Annual costs | ||||
USA | NR | Patient | Medical services | Adults with ID: $32,630 Adults without ID:$16,316 | NR | NR | Annual costs | |||
NR | Patient | Medical | Children with ID: $18,645 Children without ID: $9323 | NR | NR | Annual costs | ||||
Horlin et al. (2014) [14] | Australia | To compare expenses between families whose children receiving immediate versus delayed diagnoses | Survey (Respondents: parents) | N = 521 (< 18 years old) | Patient | All healthcare | OOP: $6937 | 30,422 (loss of income of the parents and caregivers) | 35,593 | Annual costs |
Lavelle et al. (2014) [12] | USA | To estimate the associations between ASD diagnoses and service use, caregiver time, and cost outcomes | Secondary analysis of data (National Health Interview Survey) and a study-specific survey | N = 258 (3–17 years old) | Patient Payer | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | Insurer spending: $3618 OOP: $218 | NR | NR | Annual costs |
Thomas et al. (2014) [39] | USA | To investigate the association between school transition age and healthcare expenditures for children with ASD | Secondary analysis of data (Pooled data from the Medical Expenditure Panel Survey) | N = 337 (< 21 years old) | Patient | All healthcare | Median OOP: $490 | NR | NR | Annual costs |
Barrett et al. (2015) [40] | UK | To describe the services and associated costs for individual with ASD and | Cohort of adolescents with ASD and other special needs | N = 51(adolescents with autistic disorder) (9–14 years) | Provider | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | Provider spending: $1231 | NR | NR | 6 months |
N = 45 (adolescents with other ASDs) (9–14 years) | Provider spending: $1999 | NR | NR | |||||||
Byford et al. (2015) [41] | UK | To investigate the cost-effectiveness of a communication-focused therapy for pre-school children with ASD | Cohort study | N = 77 (PACT+ treatment as usual) (2–4 years) | Provider Patient | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | OOP: $2896 Provider spending: $16,523 | $1223 | $20,645 | 13 months |
N = 75 (treatment as usual) (2–4 years) | Provider Patient | OOP: $1990 Provider spending: $5180 | $842 | $7923 | ||||||
Parish et al. (2015) [42] | USA | To investigate the relationship between family financial burden and children’s health | Secondary analysis of data (Pooled 2000–2009 Medical Expenditure Panel Survey data) | N = 316 (< 18 years old) | Patient | NR | OOP: $904 | NR | NR | Annual costs |
Thomas et al. (2016) [43] | USA | To examine expenditures according to types of health insurance included private alone, Medicaid alone, and combined private and wrap-around Medicaid | Secondary analysis of data (Pooled data from the Medical Expenditure Panel Survey) | N = 346 (< 18 years old) | Patient | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | OOP for Medicaid insured children: $156 OOP for private insured children: $1579 Medicaid spending: $8383 Private insurance spending: $3736 | NR | NR | Annual costs |
Barry et al. (2017) [44] | USA | To measure whether implementing autism mandates altered service use or spending among commercially insured children with ASD | Secondary analysis of data (Health insurance claim: Data from three national insurers) | N = 106,977 (< 21 years old) | Payer | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | Mandate eligible: $767 Mandate ineligible: $600 | NR | NR | Monthly |
Chang et al. (2018) [45] | Taiwan | To compare the differences in dental utilization and expenditure between children and adolescents with and without ASD | Secondary analysis of data (Health insurance claim: The database of the National Health Research Institutes) | N = 1305 (< 18 years old) | Payer | Dental treatment | Insurer spending: $110 | NR | NR | Annual costs |
Vohra et al. (2017) [46] | USA | To investigate the prevalence and association of comorbidities with healthcare utilization and expenditures of fee-for service enrolled adults with and without ASD | Secondary analysis of data (Health insurance claim: Medicaid data) | N = 1772 (22–64 years) | Payer | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | Insurer spending: $16,928 | NR | NR | Annual costs |
Candon et al. (2019) [47] | USA | To investigate whether mandates have heterogeneous effects on healthcare expenditure by insures and individuals with ASD | Secondary analysis of data (Health insurance claim) | N = 106,977
(< 21 years old) | Patient Payer | NR | OOP: $124 Insurer spending: $453 | NR | NR | Monthly |
Hong et al. (2019) [48] | South Korea | To estimate the economic burden of ASD in South Korea | Secondary analysis of data (Health insurance claim: The National Health Insurance Service) | N = 5653 (1–89 years) | Patient | Hospital/inpatient services Home/community-based/outpatient services | NR | NR | $2496 | Annual costs |
Li et al. (2019) [49] | Taiwan | To examine the cost and utilization of rehabilitation resources among children with ASD | Secondary analysis of data (Health insurance claim: The National Health Insurance Research Database) | N = 3227 (3–12 years) | Payer | Home/community-based/outpatient services | Insurer spending: $2100 | NR | NNRM | Annual costs |
Roddy and O’Neill (2019) [50] | Ireland | To measure the societal cost of childhood ASDs | Survey (Respondents: parents) | N = 222 (2–18 years) | Patient | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | OOP: $2756 | NR | NR | Annual costs |
Zerbo et al. (2019) [11] | USA | To compare healthcare utilization patterns and cost among insured adults with ASD, adults with ADHD and adults with neither condition | Secondary analysis of data (Administrative claim data: The Kaiser Permanente Northern California (KPNC) database | N = 1507 (> 18 years) | Provider | Hospital/inpatient services Home/community-based/outpatient services Respite care Other | Provider spending: $7889 | NR | NNRM | Annual costs |
Zuvekas et al. (2021) [51] | USA | To estimate healthcare costs for US children with ASD | Secondary analysis of data (Two different surveys) | N = 45,944 (3–17 years) | Patient | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | Medical Expenditure Panel Survey (MEPS: $4163 National Health Interview Survey (NHIS): $5955 | NR | NR | Annual costs |
Höfer et al. (2022) [52] | Germany | To estimate health service use and associated costs in children, adolescents and adults with ASD with and without intellectual disability | Survey (Respondents: parents) | N = 385 (4–67 years) | Patients | Hospital/inpatient services Home/community-based/outpatient services Respite care Other | $4208 | NR | NR | Annual costs |
Ames et al. (2021) [53] | USA | To calculate healthcare service utilization and cost among transition-age youth with ASD and other special healthcare needs | Secondary analysis of data (Administrative claim: Kaiser Permanente Northern California) | N = 4123 (14–25 years) | Provider | Hospital/inpatient services Home/community-based/outpatient services Respite care Medication use Other | Provider spending: $5302 | NR | NR | Annual costs |
Direct healthcare costs
Indirect costs
Key determinants of healthcare costs among individuals with ASD
Determinants of healthcare costs | Study |
---|---|
Severity of ASD (+) | (Järbrink and Knapp 2001), (Sharpe and Baker 2007), (Barrett, Byford et al. 2012), (Barrett, Byford et al. 2012), (Raz, Lerner-Geva et al. 2013), (Horlin, Falkmer et al. 2014), (Roddy and O’Neill 2019) |
Associated disabilities (+) | (Järbrink and Knapp 2001), (Järbrink 2007), (Peacock, Amendah et al. 2012), (Lavelle, Weinstein et al. 2014), (Thomas, Parish et al. 2014), (Vohra, Madhavan et al. 2017), (Roddy and O’Neill 2019), (Page, McKenzie et al. 2021), (Buescher, Cidav et al. 2014) |
Utilizing medical interventions (+) | (Sharpe and Baker 2007) |
Age (+) | (Barrett, Byford et al. 2012), (Lavelle, Weinstein et al. 2014), (Thomas, Parish et al. 2014), (Parish, Thomas et al. 2015), (Chang, Wang et al. 2018), (Hong, Lee et al. 2020), (Buescher, Cidav et al. 2014) |
Age (−) | (Barrett, Mosweu et al. 2015), (Barry, Epstein et al. 2017), (Li, Chen et al. 2019), (Page, McKenzie et al. 2021), (Research Ethics Committees Certificate 2019) |
Being male (+) | (Hong, Lee et al. 2020), |
Being female (+) | (Li, Chen et al. 2019), (Page, McKenzie et al. 2021), (Research Ethics Committees Certificate 2019) |
Income (−) | (Sharpe and Baker 2007), (Thomas, Parish et al. 2014), |
Income (+) | (Raz, Lerner-Geva et al. 2013), (Parish, Thomas et al. 2015), (Candon, Barry et al. 2019) |
Health insurance (−) | (Parish, Thomas et al. 2012), (Thomas, Williams et al. 2016) |
Rural residence (+) | (Wang, Zhou et al. 2012) |
Rural residence (−) | (Parish, Thomas et al. 2015) |
Parents’ education (+) | (Raz, Lerner-Geva et al. 2013), (Thomas, Parish et al. 2014), (Page, McKenzie et al. 2021) |
Education level among adults with ASD (−) | (Page, McKenzie et al. 2021) |
Living with parents (+) | (Raz, Lerner-Geva et al. 2013) |
Living with a single mother head of household (−) | (Thomas, Parish et al. 2014) |
Having at least one older sibling (−) | (Raz, Lerner-Geva et al. 2013) |
Delay in diagnosis (+) | (Horlin, Falkmer et al. 2014), |
Prescription medication (+) | (Lavelle, Weinstein et al. 2014), (Thomas, Parish et al. 2014) |
Private insurance (+) | (Parish, Thomas et al. 2015), |
Household size (−) | (Parish, Thomas et al. 2015) |
Being visited in teaching hospital (+) | (Li, Chen et al. 2019) |